Ticagrelor: A safe option as part of triple therapy?

  • Mohammad Umar Farooq | umar.farooq7@yahoo.com ChristianaCare Health System, Academic Affiliate of Sidney Kimmel Medical College, Thomas Jefferson University, Newark, DE, United States.

Abstract

Patients with atrial fibrillation who have concurrent coronary artery disease requiring percutaneous coronary intervention are subsequently prescribed dual antiplatelet therapy and anticoagulation resulting in triple therapy (TT). Ticagrelor, a reversibly binding P2Y12 antiplatelet agent, has shown superiority to clopidogrel in prevention of ischemic events and death, but is also associated with a small increase in the incidence of intracranial bleeding. This bleeding risk may be enhanced in the setting of TT. The objective of this report is to describe a case of a 70-year-old male prescribed TT with ticagrelor and to review the current literature on the safety of ticagrelor as a part of TT.

Google Scholar

Google Scholar

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-04-27
Info
Issue
Section
Case Reports
Keywords:
Cardiovascular disease (cardiology), clinical decision making, clinical pharmacology, antiplatelet therapy, triple therapy.
Statistics
  • Abstract views: 235

  • PDF: 119
  • HTML: 0
How to Cite
Farooq, M. U. (2020). Ticagrelor: A safe option as part of triple therapy?. Clinics and Practice, 10(1). https://doi.org/10.4081/cp.2020.1221